Morgan Stanley Sticks to Its Buy Rating for Dexcom (DXCM)
In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Dexcom, with a price target of $75.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Wood is an analyst with an average return of -1.2% and a 47.24% success rate. Wood covers the Healthcare sector, focusing on stocks such as Dexcom, RxSight, and GE Healthcare Technologies Inc.
In addition to Morgan Stanley, Dexcom also received a Buy from BTIG’s Marie Thibault in a report issued today. However, on the same day, Barclays maintained a Sell rating on Dexcom (NASDAQ: DXCM).
Based on Dexcom’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.21 billion and a net profit of $283.8 million. In comparison, last year the company earned a revenue of $994.2 million and had a net profit of $134.6 million
Read More on DXCM:
Disclaimer & DisclosureReport an Issue
- DexCom price target raised to $90 from $78 at Mizuho
- Dexcom: Solid Q4 Execution, Durable Growth Drivers, and Innovation Pipeline Underpin Buy Rating and $85 Target
- DexCom price target lowered to $95 from $99 at Canaccord
- DexCom price target raised to $72 from $71 at Barclays
- Dexcom: Sustained Revenue Outperformance and Margin Expansion Underpin Buy Rating
